“February 2022 is the goal date for the trial batch, after which we’ll apply for regulatory approvals,” YK Gupta, chairman of BIBCOL, informed ET. “We are going to begin full manufacturing of Covaxin thereafter, which shall be 10 million doses monthly.” The opposite two firms that may assist ramp up manufacturing capability of Covaxin are Haffkine Bio-Pharmaceutical Company, Mumbai, and Indian Immunologicals (IIL), Hyderabad.
The federal government is now betting on Indian Immunologicals to spice up Covaxin manufacturing this yr as Haffkine Bio-Pharma managing director Sandeep Rathod had earlier estimated a yr to start out making the vaccine.
“We anticipate that Indian Immunologicals will begin manufacturing of Covaxin by the tip of this yr,” a senior authorities official informed ET.
Bharat Biotech has signed a expertise switch pact to allow manufacturing of Covaxin pictures by these corporations. BIBCOL has appointed a advisor for upgrading its facility in Bulandshahr, Uttar Pradesh, and civil work is underway, Gupta mentioned. “The upgradation will begin quickly and by February subsequent yr we anticipate to come back out with the primary trial batch of the vaccine,” he mentioned.